Canaccord Genuity Analysts Give Endo International PLC (ENDP) a $10.00 Price Target
Endo International PLC (NASDAQ:ENDP) received a $10.00 price objective from stock analysts at Canaccord Genuity in a note issued to investors on Monday. The brokerage presently has a “hold” rating on the stock. Canaccord Genuity’s target price would suggest a potential upside of 22.85% from the stock’s current price.
Other equities analysts have also issued reports about the stock. Guggenheim assumed coverage on shares of Endo International PLC in a research report on Saturday, June 17th. They set a “hold” rating and a $12.00 target price on the stock. Cowen and Company restated a “hold” rating and set a $16.00 target price on shares of Endo International PLC in a research report on Thursday, August 10th. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a research report on Thursday, June 8th. Deutsche Bank AG lowered their target price on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating on the stock in a research report on Friday, July 7th. Finally, Royal Bank Of Canada restated a “sector perform” rating and set a $9.00 target price (down from $15.00) on shares of Endo International PLC in a research report on Wednesday, August 9th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $14.75.
Shares of Endo International PLC (ENDP) traded up 6.82% during mid-day trading on Monday, reaching $8.14. 9,971,527 shares of the company’s stock traded hands. The firm’s 50-day moving average is $10.70 and its 200 day moving average is $11.49. The firm’s market cap is $1.82 billion. Endo International PLC has a one year low of $7.41 and a one year high of $24.93.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.19. The business had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period last year, the firm posted $0.86 earnings per share. Analysts predict that Endo International PLC will post $3.52 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.americanbankingnews.com/2017/08/15/canaccord-genuity-analysts-give-endo-international-plc-endp-a-10-00-price-target.html.
In other Endo International PLC news, COO Terrance J. Coughlin bought 20,000 shares of Endo International PLC stock in a transaction on Thursday, August 10th. The stock was bought at an average price of $7.70 per share, with a total value of $154,000.00. Following the completion of the acquisition, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Campanelli bought 6,500 shares of Endo International PLC stock in a transaction on Monday, August 14th. The stock was acquired at an average cost of $7.71 per share, with a total value of $50,115.00. Following the acquisition, the chief executive officer now owns 213,620 shares of the company’s stock, valued at approximately $1,647,010.20. The disclosure for this purchase can be found here. In the last three months, insiders acquired 36,000 shares of company stock valued at $279,460. 0.50% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ENDP. OppenheimerFunds Inc. increased its position in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares during the period. Bank of New York Mellon Corp increased its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares during the period. First Quadrant L P CA purchased a new position in Endo International PLC during the first quarter valued at about $24,556,000. Teachers Advisors LLC increased its position in Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after buying an additional 15,928 shares during the period. Finally, TIAA CREF Investment Management LLC increased its position in Endo International PLC by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after buying an additional 10,387 shares during the period. 92.27% of the stock is owned by institutional investors and hedge funds.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.